Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post-Authorization Safety Study.

Autor: Spangler L; Center for Observational Research, Amgen Inc. Thousand Oaks CA USA., Nielson CM; Center for Observational Research, Amgen Inc. Thousand Oaks CA USA., Brookhart MA; NoviSci, Inc. Durham NC USA.; Department of Population Health Sciences Duke University Durham NC USA., Hernandez RK; Center for Observational Research, Amgen Inc. Thousand Oaks CA USA., Stad RK; Research and Development, Amgen Inc. Europe GmbH Rotkreuz Switzerland., Lin TC; Center for Observational Research, Amgen Inc. Thousand Oaks CA USA.
Jazyk: angličtina
Zdroj: JBMR plus [JBMR Plus] 2023 Aug 21; Vol. 7 (10), pp. e10793. Date of Electronic Publication: 2023 Aug 21 (Print Publication: 2023).
DOI: 10.1002/jbm4.10793
Abstrakt: Osteoporosis and cardiovascular disease are common in older adults. Treatment of osteoporosis reduces the burden of debilitating fractures; however, it is important to understand the benefit versus risk of treatment. This study evaluates the risk of stroke (ischemic or hemorrhagic) and myocardial infarction (MI) among postmenopausal women and men initiating osteoporosis treatment with denosumab (receptor activator of nuclear factor κB ligand [RANKL] inhibitor) or zoledronic acid (bisphosphonate) between October 2010 and June 2019. A retrospective cohort study employing the new user/active comparator design was conducted. Analyses were conducted separately in two national US commercial databases, MarketScan® and Optum® for reproducibility. Inverse probability of treatment and censoring weighting was employed to control for confounding and informative censoring. Cumulative risks at 6-month, 12-month, and 36-month time points were calculated and adjusted risk ratios and differences (with 95% confidence intervals [CIs]) were estimated. In MarketScan® and Optum® databases, 96,611 and 73,127 patients met all study eligibility criteria, respectively. At 36 months, the risk ratio estimates (zoledronic acid referent group) were 1.22 (95% CI, 0.77-1.66) and 0.97 (95% CI, 0.63-1.32) for MI and 1.00 (95% CI, 0.61-1.40) and 0.87 (95% CI, 0.56-1.17) for stroke in MarketScan and Optum, respectively. Most of the treatment associations across the other time periods and outcomes also had 95% CIs including the null value. In these large samples of real-world US patients, no increased risk in MI and stroke were identified for up to 36 months of treatment in denosumab users compared with zoledronic acid users. © 2023 Amgen. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
(© 2023 Amgen. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.)
Databáze: MEDLINE
Externí odkaz: